Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Kymera Therapeutics (KYMR) Asset Writedowns and Impairment (2024 - 2025)

Kymera Therapeutics (KYMR) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $1000.0 as the latest value for Q4 2025.

For Q4 2025, Asset Writedowns and Impairment rose 104.0% year-over-year to $1000.0; the TTM value through Dec 2025 reached $3.9 million, down 21.31%, while the annual FY2025 figure was $3.9 million, 21.31% down from the prior year.
Asset Writedowns and Impairment hit $1000.0 in Q4 2025 for Kymera Therapeutics, down from $3.9 million in the prior quarter.
Across five years, Asset Writedowns and Impairment topped out at $4.9 million in Q1 2024 and bottomed at -$25000.0 in Q4 2024.